Publications from Anticancer Antibodies 01/01/2011 – 29/03/2013

Publications from Anticancer Antibodies
01/01/2011 – 29/03/2013
In press
Bernard C, Maucort-Boulch D, Varron L, Charlier C, Sitbon K, Freymond N, Bouhour D, Hot A,
Masquelet AC, Valeyre D, Costedoat-Chalumeau N, Etienne M, Gueit I, Jouneau S, Delaval P,
Mouthon L, Pouget J, Serratrice J, Brion JP, Vaylet F, Bremont C, Chennebault JM, Jaffuel S,
Broussolle C, Lortholary O & Seve P. Cryptococcosis in sarcoidosis: cryptOsarc, a comparative
study of 18 cases. Qjm, In press.
Bernard J, Poulalhon N, Argenziano G, Debarbieux S, Dalle S & Thomas L. Dermoscopy of
dermatofibrosarcoma protuberans: a study of 15 cases. Br J Dermatol, In press.
Brackers de Hugo L, Ffrench M, Broussolle C & Seve P. Granulomatous lesions in bone marrow.
Clinicopathologic findings and significance in a study of 48 cases. Eur J Intern Med, In press.
Carrera C, Bennassar A, Ishioka P, Dalle S, Vilalta A, Fuertes I, Alos L, Thomas L, Puig S & Malvehy J.
Desmoplastic melanoma on the nose: electrochemotherapy as an alternative treatment to
local advanced disease. J Eur Acad Dermatol Venereol, In press.
Dalle S, Poulalhon N, Debarbieux S & Thomas L. Second primary melanomas under vemurafenib. Br J
Dermatol, In press.
Debarbieux S, Dalle S, Depaepe L, Poulalhon N, Balme B & Thomas L. Second primary melanomas
under BRAF blockers: study by Reflectance Confocal Microscopy. Br J Dermatol, In press.
Doleans-Jordheim A, Veron JB, Fendrich O, Bergeron E, Montagut-Romans A, Wong YS, Furdui B,
Freney J, Dumontet C & Boumendjel A. 3-Aryl-4-methyl-2-quinolones Targeting
Multiresistant Staphylococcus aureus Bacteria. ChemMedChem, In press.
Estublier C, Stankovic Stojanovic K, Bergerot JF, Broussolle C & Seve P. Myositis in a patient with
Familial Mediterranean Fever and spondyloarthritis successfully treated with Anakinra. Joint
Bone Spine, In press.
Goutelle S, Baudry T, Gagnieu MC, Boibieux A, Livrozet JM, Peyramond D, Chidiac C, Tod M & Ferry T.
Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable
HIV-infected patients. Antimicrob Agents Chemother, In press.
Grange F, Barbe C, Aubin F, Lipsker D, Granel-Brocard F, Velten M, Dalac S, Truchetet F, Michel C,
Mitschler A, Arnoult G, Buemi A, Dalle S, Bernard P & Woronoff AS. Clinical and sociodemographic characteristics of thick melanomas: a population-based, case-case study.
Archives of Dermatology, In press.
Jourdan E, Boissel N, Chevret S, Delabesse E, Renneville A, Cornillet P, Blanchet O, Cayuela JM,
Recher C, Raffoux E, Delaunay J, Pigneux A, Bulabois CE, Berthon C, Pautas C, Vey N, Lioure B,
Thomas X, Luquet I, Terre C, Guardiola P, Bene MC, Preudhomme C, Ifrah N & Dombret H.
Prospective evaluation of gene mutations and minimal residual disease (MRD) in patients
with core binding factor acute myeloid leukemia (CBF-AML). Blood, In press.
Leroy S, Gaudebout N, Lanteme P & Seve P. Recurrent pericarditis as an initial manifestation of
Wegener's granulomatosis. Ann Cardiol Angeiol (Paris), In press.
Levy-Sitbon C, Barbe C, Granel-Brocard F, Lipsker D, Aubin F, Dalac S, Truchetet F, Michel C, Mitschler
A, Arnoult G, Le Clainche A, Dalle S, Bernard P & Grange F. Diagnosis and management of
melanoma with regional lymph node metastases: a population-based study in France. J
European Acad dermatol, In press.
Martino A, Sainz J, Manuel Reis R, Moreno V, Buda G, Lesueur F, Marques H, Garcia-Sanz R, Rios R,
Stein A, Dumontet C, Gemignani F, Maria Rossi A, Landi S, Jurado M, Petrini M, Jamroziak K,
Campa D & Canzian F. Polymorphisms in regulators of xenobiotic transport and metabolism
genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context
of the IMMEnSE consortium. J Hum Genet, In press.
Reslan L, Dalle S, Herveau S, Perrial E, Tournebize C & Dumontet C. Comparison of the cytotoxic
mechanism of anti-CD20 antibodies rituximab and GA101 against fresh chronic lymphocytic
leukemia cells. Leuk Lymphoma, In press.
Saadoun D, Bodaghi B, Bienvenu B, Wechsler B, Sene D, Trad S, Abad S, Cacoub P, Kodjikian L & Seve
P. Biotherapies in inflammatory ocular disorders: Interferons, immunoglobulins, monoclonal
antibodies. Autoimmun Rev, In press.
Tagoug I, Plesa A & Dumontet C. Bortezomib influences the expression of malignant plasma cells
membrane antigens. Eur J Pharmacol, In press.
Tredan O, Manuel M, Clapisson G, Bachelot T, Chabaud S, Bardin-dit-Courageot C, Rigal C, Biota C,
Bajard A, Pasqual N, Blay JY, Caux C & Menetrier-Caux C. Patients with metastatic breast
cancer leading to CD4+ T cell lymphopenia have poor outcome. Eur J Cancer, In press.
Tredan O, Treilleux I, Wang Q, Gane N, Pissaloux D, Bonnin N, Petit T, Cretin J, Bonichon-Lamichhane
N, Priou F, Lavau-Denes S, Mari V, Freyer G, Lebrun D, Alexandre J & Ray-Coquard I.
Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a
GINECO group study. Target Oncol, In press.
2013
Almouazen E, Bourgeois S, Jordheim LP, Fessi H & Briancon S. Nano-encapsulation of Vitamin D3
Active Metabolites for Application in Chemotherapy: Formulation Study and in Vitro
Evaluation. Pharm Res, 2013, 30, (4): 1137-1146.
Buron F, Malvezzi P, Villar E, Chauvet C, Janbon B, Denis L, Brunet M, Daoud S, Cahen R, PouteilNoble C, Gagnieu MC, Bienvenu J, Bayle F, Morelon E & Thaunat O. Profiling sirolimusinduced inflammatory syndrome: a prospective tricentric observational study. PLoS One,
2013, 8, (1): e53078.
Carrabin N, Treilleux I, Meeus P, Tredan O & Ray-Coquard I. Primary ovarian borderline tumor in the
inguinal lymph node. Int J Gynecol Pathol, 2013, 32, (2): 167-170.
Clerc J, Sunyach MP, Duruisseaux M, Mignotte H, Bajard A, Tredan O & Arnaud A. Regional
recurrence of triple-negative breast cancer: Interest of systematic adjuvant lymph node
irradiation? Gynecol Obstet Fertil, 2013, 41, (2): 90-95.
Debarbieux S, Depaepe L, Poulalhon N, Balme B, Dalle S & Thomas L. Reflectance confocal
microscopy accurately discriminates between benign and malignant melanocytic lesions
exhibiting a 'dermoscopic island'. J Eur Acad Dermatol Venereol, 2013, 27, (2): e159-165.
Debarbieux S, Depaepe L, Poulalhon N, Dalle S, Balme B & Thomas L. Reflectance confocal
microscopy characteristics of eight cases of pustular eruptions and histopathological
correlations. Skin Res Technol, 2013, 19, (1): e444-452.
Deshayes E, Le Berre JP, Jouanneau E, Vasiljevic A, Raverot G & Seve P. 18F-FDG PET/CT findings in a
patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med, 2013, 38, (1): e5052.
Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E & Leroy V. Anti-viral triple
therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol, 2013, 56,
(2): 146-149.
Eljaafari A, Yuruker O, Ferrand C, Farre A, Addey C, Tartelin ML, Thomas X, Tiberghien P, Simpson E,
Rigal D & Scott D. Isolation of human CD4/CD8 double-positive, graft-versus-host diseaseprotective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLADR7-restricted HY-specific CD4 clone. J Immunol, 2013, 190, (1): 184-194.
Gardin C, Chevret S, Pautas C, Turlure P, Raffoux E, Thomas X, Quesnel B, de Revel T, de Botton S,
Gachard N, Renneville A, Boissel N, Preudhomme C, Terre C, Fenaux P, Bordessoule D, CelliLebras K, Castaigne S & Dombret H. Superior long-term outcome with idarubicin compared
with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older.
J Clin Oncol, 2013, 31, (3): 321-327.
Gupta V, Richards S, Rowe J & with Thomas X. Allogeneic, but not autologous, hematopoietic cell
transplantation improves survival only among younger adults with acute lymphoblastic
leukemia in first remission: an individual patient data meta-analysis. Blood, 2013, 121, (2):
339-350.
Jordheim LP, Marton Z, Rhimi M, Cros-Perrial E, Lionne C, Peyrottes S, Dumontet C, Aghajari N &
Chaloin L. Identification and characterization of inhibitors of cytoplasmic 5'-nucleotidase cN-II
issued from virtual screening. Biochem Pharmacol, 2013, 85, (4): 497-506.
Massa AF, Dalle S & Thomas L. Subcorneal hematoma. Ann Dermatol Venereol, 2013, 140, (1): 63-64.
Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S,
Labussiere H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini
FE & Jaisson-Hot I. Prospective study of erythropoietin use on quality of life and cost
effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell
transplantation patients. Cancer, 2013, 119, (1): 107-114.
Moulin C, Poulalhon N, Duru G, Debarbieux S, Dalle S & Thomas L. Dermoscopy use by French private
practice dermatologists: a nationwide survey. Br J Dermatol, 2013, 168, (1): 74-79.
Pavic M, Pasquet F, Fieschi C, Malphettes M & Seve P. Granulomatosis and primary
immunodeficiency in the adulthood. Rev Med Interne, 2013, 34, (3): 154-158.
Peron J, Cropet C, Tredan O, Bachelot T, Ray-Coquard I, Clapisson G, Chabaud S, Philip I, Borg C,
Cassier P, Labidi Galy I, Sebban C, Perol D, Biron P, Caux C, Menetrier-Caux C & Blay JY. CD4
lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer, 2013, 49, (5):
1080-1089.
Puntervoll HE, Yang XR, Vetti HH, Bachmann IM, Avril MF, Benfodda M, Catricala C, Dalle S, DuvalModeste AB, Ghiorzo P, Grammatico P, Harland M, Hayward NK, Hu HH, Jouary T, MartinDenavit T, Ozola A, Palmer JM, Pastorino L, Pjanova D, Soufir N, Steine SJ, Stratigos AJ,
Thomas L, Tinat J, Tsao H, Veinalde R, Tucker MA, Bressac-de Paillerets B, Newton-Bishop JA,
Goldstein AM, Akslen LA & Molven A. Melanoma prone families with CDK4 germline
mutation: phenotypic profile and associations with MC1R variants. J Med Genet, 2013, 50,
(4): 264-270.
Seve P, Broussolle C & Pavic M. Primary immunodeficiencies presenting with autoimmune cytopenias
in adults. Rev Med Interne, 2013, 34, (3): 148-153.
Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC, Escoffre M,
Huguet F, Rea D, Delannoy A, Cahn JY, Vernant JP, Ifrah N, Dombret H & Thomas X. Longterm follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo
Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study. Biol Blood
Marrow Transplant, 2013, 19, (1): 150-155.
2012
Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L,
Garderet L, Decaux O, Leyvraz S, Vekemans MC, Voillat L, Michallet M, Pegourie B, Dumontet
C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H & Harousseau JL. Lenalidomide
maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med, 2012, 366,
(19): 1782-1791.
Bally C, Fadlallah J, Leverger G, Bertrand Y, Robert A, Baruchel A, Guerci A, Recher C, Raffoux E,
Thomas X, Leblanc T, Idres N, Cassinat B, Vey N, Chomienne C, Dombret H, Sanz M, Fenaux P
& Ades L. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an
analysis in two consecutive trials of the European APL Group. J Clin Oncol, 2012, 30, (14):
1641-1646.
Barakat KH, Jordheim LP, Perez-Pineiro R, Wishart D, Dumontet C & Tuszynski JA. Virtual screening
and biological evaluation of inhibitors targeting the XPA-ERCC1 interaction. PLoS One, 2012,
7, (12): e51329.
Bernard C, Kodjikian L, Bancel B, Isaac S, Broussolle C & Seve P. Ocular sarcoidosis: when should
labial salivary gland biopsy be performed? Graefes Arch Clin Exp Ophthalmol, 2012, 251, (3):
855-860.
Boespflug A, Dalle S & Thomas L. Melanoma mimicking Reed naevus. Ann Dermatol Venereol, 2012,
139, (12): 857-858.
Bouaziz A, Le Scanff J, Chapelon-Abric C, Varron L, Khenifer S, Gleizal A, Bentz MH, Barthel A, Valeyre
D & Seve P. Oral involvement in sarcoidosis: report of 12 cases. Qjm, 2012, 105, (8): 755-767.
Bourgne C, Bamdad M, Janel A, Libert F, Gagnieu MC, Rapatel C, Pigeon P, Pereira S, Hermet E,
Guerci A, Pereira B, Makhoul PC, Ansah AJ, Cahn JY, Guyotat D, Trouillier S, Berger J, BoiretDupre N & Berger MG. Measurement of imatinib uptake by flow cytometry. Cytometry A,
2012, 81, (11): 996-1004.
Callens C, Baleydier F, Lengline E, Ben Abdelali R, Petit A, Villarese P, Cieslak A, Minard-Colin V,
Rullier A, Moreau A, Baruchel A, Schmitt C, Asnafi V, Bertrand Y & Macintyre E. Clinical
Impact of NOTCH1 and/or FBXW7 Mutations, FLASH Deletion, and TCR Status in Pediatric TCell Lymphoblastic Lymphoma. J Clin Oncol, 2012, 30, (16): 1966-1973.
Campa D, Martino A, Sainz J, Buda G, Jamroziak K, Weinhold N, Vieira Reis RM, Garcia-Sanz R, Jurado
M, Rios R, Szemraj-Rogucka Z, Marques H, Lesueur F, Bugert P, Moreno V, Szemraj J, Orciuolo
E, Gemignani F, Rossi AM, Dumontet C, Petrini M, Goldschmidt H, Landi S & Canzian F.
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma
risk in the IMMEnSE consortium. Br J Haematol, 2012, 157, (3): 331-338.
Cannas G, Pautas C, Raffoux E, Quesnel B, Botton S, Revel T, Reman O, Gardin C, Elhamri M, Boissel
N, Fenaux P, Michallet M, Castaigne S, Dombret H & Thomas X. Infectious complications in
adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802
prospective multicenter clinical trial. Leuk Lymphoma, 2012, 53, (6): 1068-1076.
Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P,
Reman O, de Revel T, Gastaud L, de Gunzburg N, Contentin N, Henry E, Marolleau JP, Aljijakli
A, Rousselot P, Fenaux P, Preudhomme C, Chevret S & Dombret H. Effect of gemtuzumab
ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701):
a randomised, open-label, phase 3 study. Lancet, 2012, 379, (9825): 1508-1516.
Dalle S, Finet A & Thomas L. Kaposi's sarcoma. Ann Dermatol Venereol, 2012, 139, (1): 73-74.
Dalle S, Parmentier L, Moscarella E, Phan A, Argenziano G & Thomas L. Dermoscopy of merkel cell
carcinoma. Dermatology, 2012, 224, (2): 140-144.
Detrait M, Dubois V, Sobh M, Morisset S, Tedone N, Labussiere H, Gillis L, Barraco F, Cannas G,
Ducastelle S, Fatoum J, Thomas X, Chelgoum Y, Nicolini FE & Michallet M. Impact of anti-HLA
antibodies on allogeneic hematopoietic stem cell transplantation outcomes after reducedintensity conditioning regimens. Exp Hematol, 2012, 40, (10): 792-799.
Dufour JF, Le Gallou T, Cordier JF, Aumaitre O, Pinede L, Aslangul E, Pagnoux C, Marie I, Puechal X,
Decaux O, Dubois A, Agard C, Mahr A, Comoz F, Boutemy J, Broussolle C, Guillevin L, Seve P &
Bienvenu B. Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and
review of the literature. Medicine (Baltimore), 2012, 91, (2): 67-74.
Dupire S, Wemeau M, Debarri H, Pascal L, Hivert B, Willekens C, Boyle E, Manier S, Beatrice T, Onraed
B, Faucompre JL, Hennache B, Dumontet C, Facon T & Leleu X. Prognostic value of PINI index
in patients with multiple myeloma. Eur J Haematol, 2012, 88, (4): 306-313.
Ebbo M, Daniel L, Pavic M, Seve P, Hamidou M, Andres E, Burtey S, Chiche L, Serratrice J, LongyBoursier M, Ruivard M, Haroche J, Godeau B, Beucher AB, Berthelot JM, Papo T, Pennaforte
JL, Benyamine A, Jourde N, Landron C, Roblot P, Moranne O, Silvain C, Granel B, Bernard F,
Veit V, Mazodier K, Bernit E, Rousset H, Boucraut J, Boffa JJ, Weiller PJ, Kaplanski G,
Aucouturier P, Harle JR & Schleinitz N. IgG4-related systemic disease: features and treatment
response in a French cohort: results of a multicenter registry. Medicine (Baltimore), 2012, 91,
(1): 49-56.
Ferry T, Senechal A, Gagnieu MC, Boibieux A, Laurent F, Perpoint T, Tod M & Chidiac C. Prolonged
subcutaneous high dose (1 g bid) of Ertapenem as salvage therapy in patients with difficultto-treat bone and joint infection. J Infect, 2012, 65, (6): 579-582.
Giebel S, Thomas X, Hallbook H, Geissler K, Boiron JM, Huguet F, Koller E, Jaeger U, Smedmyr B,
Hellmann A & Holowiecki J. The prophylactic use of granulocyte-colony stimulating factor
during remission induction is associated with increased leukaemia-free survival of adults with
acute lymphoblastic leukaemia: A joint analysis of five randomised trials on behalf of the
EWALL. Eur J Cancer, 2012, 48, (3): 360-367.
Gomez-Abreo D, Prost C, Couraud S, Parmeland L, Carret G, Boibieux A, Gagnieu MC, Geriniere L,
Avrillon V & Souquet PJ. Chronic necrotizing pulmonary aspergillosis following an infection by
Mycobacterium malmoense. Rev Mal Respir, 2012, 29, (3): 435-439.
Goncalves A, Tredan O, Villanueva C & Dumontet C. Antibody-drug conjugates in oncology: from the
concept to trastuzumab emtansine (T-DM1). Bull Cancer, 2012, 99, (12): 1183-1191.
Grange F, Barbe C, Mas L, Granel-Brocard F, Lipsker D, Aubin F, Velten M, Dalac S, Truchetet F, Michel
C, Mitschler A, Arnoult G, Buemi A, Dalle S, Reuter G, Bernard P, Woronoff AS & Arnold F.
The role of general practitioners in diagnosis of cutaneous melanoma: a population-based
study in France. Br J Dermatol, 2012, 167, (6): 1351-1359.
Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, CornilletLefebvre P, Plesa A, Huet S, Renneville A, Salles G, Nicolini FE, Magaud JP & Michallet M. High
DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia.
PLoS One, 2012, 7, (12): e51527.
Hospital MA, Thomas X, Castaigne S, Raffoux E, Pautas C, Gardin C, Bourhis JH, Reman O, de Revel T,
Terre C, Preudhomme C, Fenaux P, Michallet M, Socie G & Dombret H. Evaluation of
allogeneic hematopoietic SCT in younger adults with adverse karyotype AML. Bone Marrow
Transplant, 2012, 47, (11): 1436-1441.
Joly P, Gagnieu MC, Bardel C, Francina A, Pondarre C & Martin C. Genotypic screening of the main
opiate-related polymorphisms in a cohort of 139 sickle cell disease patients. Am J Hematol,
2012, 87, (5): 534-536.
Jordheim LP, Ben Larbi S, Fendrich O, Ducrot C, Bergeron E, Dumontet C, Freney J & DoleansJordheim A. Gemcitabine is active against clinical multiresistant Staphylococcus aureus
strains and is synergistic with gentamicin. Int J Antimicrob Agents, 2012, 39, (5): 444-447.
Julia F, Thomas L & Dalle S. New therapeutical strategies in the treatment of metastatic disease.
Dermatol Ther, 2012, 25, (5): 452-457.
Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC,
Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysak D, Minden M &
Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient
choice, with physician advice, of either supportive care or low-dose cytarabine for the
treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol,
2012, 30, (21): 2670-2677.
Langrand C, Bihan H, Raverot G, Varron L, Androdias G, Borson-Chazot F, Brue T, Cathebras P, Pinede
L, Muller G, Broussolle C, Cotton F, Valeyre D & Seve P. Hypothalamo-pituitary sarcoidosis: a
multicenter study of 24 patients. Qjm, 2012, 105, (10): 981-995.
Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R,
Lambert JM, Ozoux ML, Poncelet P, San Miguel JF, Legrand O, Deangelo DJ, Giles FJ & Marie
JP. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult
patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs, 2012, 30, (3):
1121-1131.
Le MP, Solas C, Garraffo R, Gagnieu MC, Muret P, Yeni P, Dhiver C, Katlama C, Poizot-Martin I, Durant
J & Peytavin G. Pharmacokinetic interaction between maraviroc and etravirine in HIVinfected patients receiving regimens containing both drugs and no ritonavir-boosted
protease inhibitor. J Antimicrob Chemother, 2012, 67, (11): 2779-2781.
Le Tourneau C, Kamal M, Tredan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T,
Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet
S, Rio Frio T & Paoletti X. Designs and challenges for personalized medicine studies in
oncology: focus on the SHIVA trial. Target Oncol, 2012, 7, (4): 253-265.
Manuel M, Tredan O, Bachelot T, Clapisson G, Courtier A, Parmentier G, Rabeony T, Grives A, Perez S,
Mouret JF, Perol D, Chabaud S, Ray-Coquard I, Labidi-Galy I, Heudel P, Pierga JY, Caux C, Blay
JY, Pasqual N & Menetrier-Caux C. Lymphopenia combined with low TCR diversity (divpenia)
predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology, 2012,
1, (4): 432-440.
Marechal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, BardierDupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, Andre T, Dumontet C,
Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Deviere J, Emile JF & Van Laethem JL.
Levels of gemcitabine transport and metabolism proteins predict survival times of patients
treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology, 2012, 143, (3):
664-674 e666.
Martino A, Campa D, Buda G, Sainz J, Garcia-Sanz R, Jamroziak K, Reis RM, Weinhold N, Jurado M,
Rios R, Szemraj-Rogucka Z, Marques H, Szemraj J, Stein A, Kumar R, Orciuolo E, Gemignani F,
Landi S, Goldschmidt H, Petrini M, Dumontet C, Canzian F & Rossi AM. Polymorphisms in
xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a
case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE)
consortium. Leukemia, 2012, 26, (6): 1419-1422.
Martino A, Campa D, Jamroziak K, Reis RM, Sainz J, Buda G, Garcia-Sanz R, Lesueur F, Marques H,
Moreno V, Jurado M, Rios R, Szemraj-Rogucka Z, Szemraj J, Tjonneland A, Overvad K,
Vangsted AJ, Vogel U, Mikala G, Kadar K, Szombath G, Varkonyi J, Orciuolo E, Dumontet C,
Gemignani F, Rossi AM, Landi S, Petrini M, Houlston RS, Hemminki K & Canzian F. Impact of
polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. Br J
Haematol, 2012, 158, (6): 805-809.
Martino A, Sainz J, Buda G, Jamroziak K, Reis RM, Garcia-Sanz R, Jurado M, Rios R, Szemraj-Rogucka Z,
Marques H, Lesueur F, Moreno V, Orciuolo E, Gemignani F, Landi S, Rossi AM, Dumontet C,
Petrini M, Campa D & Canzian F. Genetics and molecular epidemiology of multiple myeloma:
the rationale for the IMMEnSE consortium (review). Int J Oncol, 2012, 40, (3): 625-638.
Maubec E, Chaudru V, Mohamdi H, Blondel C, Margaritte-Jeannin P, Forget S, Corda E, Boitier F, Dalle
S, Vabres P, Perrot JL, Lyonnet DS, Zattara H, Mansard S, Grange F, Leccia MT, Vincent-Fetita
L, Martin L, Crickx B, Joly P, Thomas L, Bressac-de Paillerets B, Avril MF & Demenais F.
Familial melanoma: clinical factors associated with germline CDKN2A mutations according to
the number of patients affected by melanoma in a family. J Am Acad Dermatol, 2012, 67, (6):
1257-1264.
Michallet M, Benet T, Sobh M, Kraghel S, El Hamri M, Cannas G, Nicolini FE, Labussiere H, Ducastelle
S, Barraco F, Thomas X, Chelghoum Y, Nicolle MC, Bienvenu AL, Persat F, De Monbrison F,
Picot S & Vanhems P. Invasive aspergillosis: an important risk factor on the short- and longterm survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis, 2012,
31, (6): 991-997.
Miller LM, Huang Yang CP, Xiao H, Isaac S, Seve P, Dumontet C, Band Horwitz S & Hogue Angeletti R.
A label-free mass spectrometry method for relative quantitation of beta-tubulin isotype
expression in human tumor tissue. Proteomics Clin Appl, 2012, 6, (9-10): 502-506.
Milley S, Bories N, Balme B, Thomas L & Dalle S. Indolent CD8+ lymphoid proliferation on the nose.
Ann Dermatol Venereol, 2012, 139, (12): 812-817.
Pasquet F, Kodjikian L, Mura F, Riviere S, Harroche J, Blanc AP, Chaix F, Oksenhendler E & Seve P.
Uveitis and common variable immunodeficiency: data from the DEF-I study and literature
review. Ocul Immunol Inflamm, 2012, 20, (3): 163-170.
Pauwels PJ, Dumontet C, Reichert JM, Beck A, Goetsch L, Corvaia N, Klein C, Coiffier B & Teicher B.
7th cancer scientific forum of the canceropole lyon auvergne rhone-alpes: march 20-21,
2012, lyon, france. MAbs, 2012, 4, (4): 434-444.
Peron J, Tredan O, Ray-Coquard I, Bachelot T, Labidi Galy SI, Favier B, Treilleux I & Guastalla JP. Firstline endocrine therapy alone could be a reasonable treatment option for hormone-positive,
HER2-positive metastatic breast cancer. Bull Cancer, 2012, 99, (2): E18-25.
Peyrouze P, Guihard S, Grardel N, Berthon C, Pottier N, Pigneux A, Cahn JY, Bene MC, Lheritier V,
Delabesse E, Macintyre E, Thomas X, Dombret H, Ifrah N & Cheok M. Genetic polymorphisms
in ARID5B, CEBPE, IKZF1 and CDKN2A in relation with risk of acute lymphoblastic leukaemia
in adults: a Group for Research on Adult Acute Lymphoblastic Leukaemia (GRAALL) study. Br J
Haematol, 2012, 159, (5): 599-613.
Poulard C, Treilleux I, Lavergne E, Bouchekioua-Bouzaghou K, Goddard-Leon S, Chabaud S, Tredan O,
Corbo L & Le Romancer M. Activation of rapid oestrogen signalling in aggressive human
breast cancers. EMBO Mol Med, 2012, 4, (11): 1200-1213.
Pralong P, Bathelier E, Dalle S, Poulalhon N, Debarbieux S & Thomas L. Dermoscopy of lentigo
maligna melanoma: report of 125 cases. Br J Dermatol, 2012, 167, (2): 280-287.
Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, Barette C, Soleilhac E, Filhol
O, Beghin A, Valdameri G, Honore S, Aci-Seche S, Grierson D, Antonipillai J, Li R, Di Pietro A,
Dumontet C, Braguer D, Florent JC, Knapp S, Bernard O & Lafanechere L. Pharmacological
inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res,
2012, 72, (17): 4429-4439.
Rahmi A, Deshayes E, Maucort-Boulch D, Varron L, Grange JD, Kodjikian L & Seve P. Intraocular
sarcoidosis: association of clinical characteristics of uveitis with findings from 18F-labelled
fluorodeoxyglucose positron emission tomography. Br J Ophthalmol, 2012, 96, (1): 99-103.
Reiman T, Lai R, Veillard AS, Paris E, Soria JC, Rosell R, Taron M, Graziano S, Kratzke R, Seymour L,
Shepherd FA, Pignon JP & Seve P. Cross-validation study of class III beta-tubulin as a
predictive marker for benefit from adjuvant chemotherapy in resected non-small-cell lung
cancer: analysis of four randomized trials. Ann Oncol, 2012, 23, (1): 86-93.
Renneville A, Boissel N, Nibourel O, Berthon C, Helevaut N, Gardin C, Cayuela JM, Hayette S, Reman
O, Contentin N, Bordessoule D, Pautas C, Botton S, Revel T, Terre C, Fenaux P, Thomas X,
Castaigne S, Dombret H & Preudhomme C. Prognostic significance of DNA methyltransferase
3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute
Leukemia French Association. Leukemia, 2012, 26, (6): 1247-1254.
Rhondali W, Perceau E, Berthiller J, Saltel P, Trillet-Lenoir V, Tredan O, Coulon JP, Bruera E & Filbet
M. Frequency of depression among oncology outpatients and association with other
symptoms. Support Care Cancer, 2012, 20, (11): 2795-2802.
Rhondali W, Perceau E, Saltel P, Trillet-Lenoir V, Blay JY, Fournel-Federico C, Coulon JP, Tredan O,
Terra JL, Matillon Y, Bruera E & Filbet M. Depression assessment by oncologists and palliative
care physicians. Palliat Support Care, 2012: 1-9.
Rivet C, Caron N, Lachaux A, Morel B, Pracros JP, Francina A, Gagnieu MC & Joly P. Association of a
glucose-6-phosphate deficiency and a Gilbert syndrome as risk factors for a severe
choledocholithiasis in a 2-month-old male infant. Pediatr Blood Cancer, 2012, 58, (2): 316.
Romieu I, Touillaud M, Ferrari P, Bignon YJ, Antoun S, Berthouze-Aranda S, Bachmann P, Duclos M,
Ninot G, Romieu G, Senesse P, Behrendt J, Balosso J, Pavic M, Kerbrat P, Serin D, Tredan O &
Ferverts B. Activité physique et survie après cancer. Bull Cancer, 2012, 99, (10): 979-994.
Schmitt C, Bouteille C, Faure C, Mignotte H, Tredan O, Bachelot T, Guastalla JP, Arnaud A, Treilleux I
& Carrabin N. Adjuvant treatments in breast cancer: interest of completion of axillary
dissection in case of micrometastases or isolated tumor cells in sentinel lymph node. Bull
Cancer, 2012, 99, (4): 463-469.
Seve P, Varron L, Broussolle C, Denis P & Kodjikian L. Sarcoid-related Uveitis Occurring During
Adalimumab Therapy. Ocul Immunol Inflamm, 2012, 20, (1): 59-60.
Solas C & Gagnieu MC. Evidence-based Therapeutic Drug Monitoring for Efavirenz. Therapie, 2012,
66, (3): 197-205.
Thomas X. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert
Opin Investig Drugs, 2012, 21, (6): 871-878.
Thomas X. Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia
and tyrosine kinase inhibitor therapy. World J Stem Cells, 2012, 4, (6): 44-52.
Thomas X. DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first
therapeutic experiences. Expert Opin Drug Discov, 2012, 7, (11): 1039-1051.
Thomas X. Intérêt du priming dans le traitement de la leucémie aiguë myéloïde. Hématologie, 2012,
18: 354-362.
Thomas X. Acute myeloid leukemia in the elderly. International Journal of Hematologic Oncology,
2012, 1: 57-69.
Thomas X. Emerging treatment approaches in acute lymphoblastic and acute myeloid leukemias.
Blood and Lymphatic Cancer: Targets and Therapy, 2012, 2: 57-76.
Thomas X, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C, Gardin C,
Chelghoum Y, Boissel N, Quesnel B, Cordonnier C, Bourhis JH, Elhamri M, Fenaux P,
Preudhomme C, Socie G, Michallet M, Castaigne S & Dombret H. Outcome of treatment after
first relapse in younger adults with acute myeloid leukemia initially treated by the ALFA-9802
trial. Leuk Res, 2012, 36, (9): 1112-1118.
Varron L, Cottin V, Schott AM, Broussolle C & Seve P. Late-onset sarcoidosis: a comparative study.
Medicine (Baltimore), 2012, 91, (3): 137-143.
Villani AP, Thomas L & Dalle S. Pectoral nodule: nodular melanoma. Ann Dermatol Venereol, 2012,
139, (5): 415-416.
Zeinyeh W, Mahiout Z, Radix S, Lomberget T, Dumoulin A, Barret R, Grenot C, Rocheblave L, Matera
EL, Dumontet C & Walchshofer N. Progesterone-adenine hybrids as bivalent inhibitors of Pglycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological
evaluation. Steroids, 2012, 77, (12): 1177-1191.
2011
Androdias G, Maillet D, Marignier R, Pinede L, Confavreux C, Broussolle C, Vukusic S & Seve P.
Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy.
Neurology, 2011, 76, (13): 1168-1172.
Aouali N, El Btaouri H, Dumontet C, Eddabra L, Malagarie-Cazenave S, Madoulet C & Morjani H.
Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in
multidrug-resistant human sarcoma cells. Oncol Rep, 2011, 25, (4): 1161-1167.
Arnaud O, Boumendjel A, Geze A, Honorat M, Matera EL, Guitton J, Stein WD, Bates SE, Falson P,
Dumontet C, Di Pietro A & Payen L. The acridone derivative MBLI-87 sensitizes breast cancer
resistance protein-expressing xenografts to irinotecan. Eur J Cancer, 2011, 47, (4): 640-648.
Asmane I, Kurtz JE, Bajard A, Guastalla JP, Meeus P, Tredan O, Labidi Galy I, Moullet I, Ardisson P,
Vincent L, Coeffic D, Dufresne A, Bergerat JP & Ray-Coquard I. Bevacizumab plus microtubule
targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. Bull
Cancer, 2011, 98, (9): 80-89.
Baleydier F, Domenech C & Thomas X. Novel conventional therapies in onco-hemathology. Bull
Cancer, 2011, 98, (8): 901-913.
Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P, Thomas X, Lepretre S, Huguet F,
Vey N, Escoffre-Barbe M, Tavernier E, Reman O, Fegueux N, Turlure P, Rousselot P, Cahn JY,
Lheritier V, Chalandon Y, Bene MC, Macintyre E, Dombret H & Ifrah N. Pediatric-inspired
intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7
mutations, but not of low ERG/BAALC expression: a GRAALL study. Blood, 2011, 118, (19):
5099-5107.
Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H,
Remenieras A, Maubec E, de la Fouchardiere A, Molinie V, Vabres P, Dalle S, Poulalhon N,
Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL,
Labeille B, Robert C, Escudier B, Caron O, Brugieres L, Saule S, Gardie B, Gad S, Richard S,
Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E,
Lidereau R, Bahadoran P, Vielh P, Corda E, Blanche H, Zelenika D, Galan P, Aubin F, Bachollet
B, Becuwe C, Berthet P, Bignon YJ, Bonadona V, Bonafe JL, Bonnet-Dupeyron MN, Cambazard
F, Chevrant-Breton J, Coupier I, Dalac S, Demange L, d'Incan M, Dugast C, Faivre L, VincentFetita L, Gauthier-Villars M, Gilbert B, Grange F, Grob JJ, Humbert P, Janin N, Joly P, Kerob D,
Lasset C, Leroux D, Levang J, Limacher JM, Livideanu C, Longy M, Lortholary A, StoppaLyonnet D, Mansard S, Mansuy L, Marrou K, Mateus C, Maugard C, Meyer N, Nogues C,
Souteyrand P, Venat-Bouvet L, Zattara H, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril
MF, Demenais F, Ballotti R & Bressac-de Paillerets B. A SUMOylation-defective MITF germline
mutation predisposes to melanoma and renal carcinoma. Nature, 2011, 480, (7375): 94-98.
Caprano V, Zane L, Poncet D, Galia P, Preudhomme C, Bonnefoy-Berard N, Gilson E, Thomas X,
Elhamri M, Chelghoum Y, Michallet M, Wattel E, Mortreux F & Sibon D. Telomere
deregulations possess cytogenetic, phenotype, and prognostic specificities in acute
leukemias. Exp Hematol, 2011, 39: 195-202.
Cassier PA, Treilleux I, Bachelot T, Ray-Coquard I, Bendriss-Vermare N, Menetrier-Caux C, Tredan O,
Goddard-Leon S, Pin JJ, Mignotte H, Bathelemy-Dubois C, Caux C, Lebecque S & Blay JY.
Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in nonmetastatic breast cancer. BMC Cancer, 2011, 11: 213.
Cosset E, Hamdan G, Jeanpierre S, Voeltzel T, Sagorny K, Hayette S, Mahon FX, Dumontet C, Puisieux
A, Nicolini FE & Maguer-Satta V. Deregulation of TWIST-1 in the CD34+ compartment
represents a novel prognostic factor in chronic myeloid leukemia. Blood, 2011, 117, (5):
1673-1676.
Dalle S, Poulalhon N & Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J
Med, 2011, 365, (15): 1448-1449; author reply 1450.
Dalle S, Reslan L, Besseyre de Horts T, Herveau S, Herting F, Plesa A, Friess T, Umana P, Klein C &
Dumontet C. Preclinical studies on the mechanism of action and the anti-lymphoma activity
of the novel anti-CD20 antibody GA101. Mol Cancer Ther, 2011, 10, (1): 178-185.
Dalle S, Sureda N & Thomas L. Pigmented lesion on the left breast. Ann Dermatol Venereol, 2011,
138, (1): 69-70.
Dalle S, Thomas L & Shear NH. How pharmacogenomics of biological response modifiers will
influence clinical response and toxicity in dermatology. Int J Dermatol, 2011, 50, (1): 114-118.
Doleans-Jordheim A, Bergeron E, Bereyziat F, Ben-Larbi S, Dumitrescu O, Mazoyer MA, Morfin F,
Dumontet C, Freney J & Jordheim LP. Zidovudine (AZT) has a bactericidal effect on
enterobacteria and induces genetic modifications in resistant strains. Eur J Clin Microbiol
Infect Dis, 2011, 30, (10): 1249-1256.
Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S,
Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I,
Liens D, Godfrin Y, Rigal D & Bertrand Y. L-asparaginase loaded red blood cells in refractory or
relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL
2005-01 randomized trial. Br J Haematol, 2011, 153, (1): 58-65.
Dumontet C. Antitubulin agents. Bull Cancer, 2011, 98, (11): 1275-1285.
Gallier F, Lallemand P, Meurillon M, Jordheim LP, Dumontet C, Perigaud C, Lionne C, Peyrottes S &
Chaloin L. Structural Insights into the Inhibition of Cytosolic 5'-Nucleotidase II (cN-II) by
Ribonucleoside 5'-Monophosphate Analogues. PLoS Comput Biol, 2011, 7, (12): e1002295.
Galy G, Labidi-Galy SI, Perol D, Bachelot T, Ray-Coquard I, Tredan O, Biron P, Latour JF, Blay JY,
Guastalla JP & Favier B. Chemotherapy for metastatic breast cancer. Comparison of clinical
practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. Breast
Cancer Res Treat, 2011, 128, (1): 187-195.
Gillibert-Duplantier J, Duthey B, Sisirak V, Salaun D, Gargi T, Tredan O, Finetti P, Bertucci F, Birnbaum
D, Bendriss-Vermare N & Badache A. Gene expression profiling identifies sST2 as an effector
of ErbB2-driven breast carcinoma cell motility, associated with metastasis. Oncogene, 2011,
31, (30): 3516-3524.
Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne A, Bonnotte B, DeRevel
T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard M, Seve P, Smail A, Viallard JF,
Godeau B, Hermine O & Michel M. Efficacy and safety of rituximab in common variable
immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33
patients. Br J Haematol, 2011, 155, (4): 498-508.
Gougounon A, Abahssain H, Rigollet L, Elhamri M, Tigaud I, Chelghoum Y, Plesa A, Dumontet C,
Michallet M & Thomas X. Minimally differentiated acute myeloid leukemia (FAB AML-M0):
prognostic factors and treatment effects on survival--a retrospective study of 42 adult cases.
Leuk Res, 2011, 35, (8): 1027-1031.
Hage-Sleiman R, Herveau S, Matera EL, Laurier JF & Dumontet C. Silencing of tubulin binding
cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity
to gemcitabine in breast cancer cells. Mol Cancer Ther, 2011, 10, (2): 303-312.
Heudel PE, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP & Bachelot T. Antihormonal therapy in
breast cancer and mTOR inhibitors. Bull Cancer, 2011, 98, (12): 1431-1437.
Honorat M, Falson P, Terreux R, Di Pietro A, Dumontet C & Payen L. Multidrug resistance ABC
transporter structure predictions by homology modeling approaches. Curr Drug Metab, 2011,
12, (3): 268-277.
Honorat M, Mesnier A, Vendrell J, Di Pietro A, Lin V, Dumontet C, Cohen P & Payen L. MRP8/ABCC11
expression is regulated by dexamethasone in breast cancer cells and is associated to
progesterone receptor status in breast tumors. Int J Breast Cancer, 2011, 2011: 807380.
Hunault-Berger M, Leguay T, Thomas X, Legrand O, Huguet F, Bonmati C, Escoffre-Barbe M, Legros L,
Turlure P, Chevallier P, Larosa F, Garban F, Reman O, Rousselot P, Dhedin N, Delannoy A,
Lafage-Pochitaloff M, Bene MC, Ifrah N & Dombret H. A randomized study of pegylated
liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute
lymphoblastic leukemia: the GRAALL-SA1 study. Haematologica, 2011, 96, (2): 245-252.
Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terre C, Fenaux P, Castaigne S,
Dombret H & Boissel N. Impact of post-remission therapy in patients aged 65-70 years with
de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials
with overlapping age inclusion criteria. Haematologica, 2011, 96, (6): 837-844.
Jordheim LP. Further evidences for pharmacogenetic assessment of nucleoside analogue-treated
patients. Leuk Res, 2011, 35, (4): 429-430.
Jordheim LP, Plesa A, Dreano M, Cros-Perrial E, Keime C, Herveau S, Demangel D, Vendrell JA &
Dumontet C. Sensitivity and gene expression profile of fresh human acute myeloid leukemia
cells exposed ex vivo to AS602868. Cancer Chemother Pharmacol, 2011, 68, (1): 97-105.
Jordheim LP, Seve P, Tredan O & Dumontet C. The ribonucleotide reductase large subunit (RRM1) as
a predictive factor in patients with cancer. Lancet Oncol, 2011, 12, (7): 693-702.
Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F,
Cassignol A, Tredan O, Durand I, Menetrier-Caux C, Caux C, Blay JY, Ray-Coquard I &
Bendriss-Vermare N. Quantitative and functional alterations of plasmacytoid dendritic cells
contribute to immune tolerance in ovarian cancer. Cancer Res, 2011, 71, (16): 5423-5434.
Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, Bienvenu AL, Picot S, Nicolle MC &
Vanhems P. Risk factors for invasive aspergillosis in acute myeloid leukemia patients
prophylactically treated with posaconazole. Med Mycol, 2011, 49, (7): 681-687.
Nguyen AM, Seve P, Le Scanff J, Gambrelle J, Fleury J, Broussolle C, Grange JD & Kodjikian L. Clinical
and etiological aspects of uveitis: a retrospective study of 121 patients referred to a tertiary
centre of ophthalmology. Rev Med Interne, 2011, 32, (1): 9-16.
Nguyen-Dumont T, Jordheim LP, Michelon J, Forey N, McKay-Chopin S, Sinilnikova O, Le Calvez-Kelm
F, Southey MC, Tavtigian SV & Lesueur F. Detecting differential allelic expression using highresolution melting curve analysis: application to the breast cancer susceptibility gene CHEK2.
BMC Med Genomics, 2011, 4: 39.
Nicolle MC, Benet T, Thiebaut A, Bienvenu AL, Voirin N, Duclos A, Sobh M, Cannas G, Thomas X,
Nicolini FE, De Monbrison F, Piens MA, Picot S, Michallet M & Vanhems P. Invasive
aspergillosis in patients with hematologic malignancies: incidence and description of 127
cases enrolled in a single institution prospective survey from 2004 to 2009. Haematologica,
2011, 96, (11): 1685-1691.
Phan A, Dalle S, Marcilly MC, Bergues JP & Thomas L. Benign dermoscopic parallel ridge pattern
variants. Arch Dermatol, 2011, 147, (5): 634.
Phan A, Dalle S & Thomas L. Hairpin vessels. Ann Dermatol Venereol, 2011, 138, (6-7): 542-544.
Plesa A, Thomas X, Le QH, Michallet AS, Dubois V, Dumontet C & Michallet M. A comparison of flow
cytometry detection of minimal residual disease and chimerism kinetics in chronic
lymphocytic leukemia patients after allogeneic hematopoietic stem cell transplantation. J
Biomed Sci Eng, 2011, 4: 173-179.
Puech R, Gagnieu MC, Planus C, Charpiat B, Boibieux A, Ferry T & Tod M. Extreme bradycardia due to
multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing
lopinavir-ritonavir. Br J Clin Pharmacol, 2011, 71, (4): 621-623.
Renneville A, Boissel N, Helevaut N, Nibourel O, Terre C, Pautas C, Gardin C, Thomas X, Turlure P,
Reman O, Berthon C, Dombret H, Castaigne S & Preudhomme C. Wilms' tumor 1 singlenucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid
leukemia. Leukemia, 2011, 25, (12): 1918-1921.
Rolin MA, Kodjikian L, Varron L, Nguyen AM, Grange JD, Broussolle C & Seve P. Characteristics of
uveitis presenting for the first time in the elderly: analysis of 91 patients in a tertiary center.
Ocular Immunol Inflamm, 2011, 19: 219-226.
Seve P & Lega JC. Kawasaki disease in adult patients. Rev Med Interne, 2011, 32, (1): 17-25.
Seve P & Pavic M. Sarcoidosis: What's new in 2010 for internists? Rev Med Interne, 2011, 32, (2): 7172.
Sureda N, Phan A, Poulalhon N, Balme B, Dalle S & Thomas L. Conservative surgical management of
subungual (matrix derived) melanoma: report of seven cases and literature review. Br J
Dermatol, 2011, 165, (4): 852-858.
Sureda N, Thomas L, Bathelier E, Balme B, Depaepe L & Dalle S. Bullous lymphomatoid papulosis. Clin
Exp Dermatol, 2011, 36, (7): 800-801.
Tagoug I, Sauty De Chalon A & Dumontet C. Inhibition of IGF-1 signalling enhances the apoptotic
effect of AS602868, an IKK2 inhibitor, in multiple myeloma cell lines. PLoS One, 2011, 6, (7):
e22641.
Thomas X. Is AP24534 (Ponatinib) the next treatment of Philadelphia chromosome-positive acute
lymphoblastic leukemia? Bull Cancer, 2011, 98, (7): 761-767.
Thomas X. Chapter 16: Induction therapy in adult acute lymphoblastic leukemia. In: Leukemias:
Principles and Practice of Therapy. Edited by Faderl S, Kantarjian H. Blackwell Publishing Ltd.
193-216: 193-216.
Thomas X & Chelghoum Y. Promyelocytic sarcoma of the sternum: a case report and review of the
literature. Korean J Hematol, 2011, 46, (1): 52-56.
Thomas X & Chelghoum Y. Lenalidomide in elderly acute myeloid leukemia (AML) patients with
deletion 5q [del(5q)]. Blood e-letter, 2011.
Thomas X, Chelghoum Y, Cannas G, Elhamri M, Labussiere H, Tigaud I, Ducastelle S, Nicolini F,
Dumontet C & Michallet M. Leukocytosis and circulating blasts in older adults with newly
diagnosed acute myeloid leukemia: are they valuable factors for therapeutic decisionmaking? Clin Lymphoma Myeloma Leuk, 2011, 11, (4): 342-349.
Thomas X, Chelghoum Y, Fanari N & Cannas G. Serum 25-hydroxyvitamin D levels are associated with
prognosis in hematological malignancies. Hematology, 2011, 16, (5): 278-283.
Thomas X, Elhamri M, Raffoux E, Renneville A, Pautas C, de Botton S, de Revel T, Reman O, Terre C,
Gardin C, Chelghoum Y, Boissel N, Quesnel B, Hicheri Y, Bourhis JH, Fenaux P, Preudhomme
C, Michallet M, Castaigne S & Dombret H. Comparison of high-dose cytarabine and timedsequential chemotherapy as consolidation for younger adults with AML in first remission: the
ALFA-9802 study. Blood, 2011, 118, (7): 1754-1762.
Tod M, Goutelle S & Gagnieu MC. Genotype-based quantitative prediction of drug exposure for drugs
metabolized by CYP2D6. Clin Pharmacol Ther, 2011, 90, (4): 582-587.
Tredan O, Ray-Coquard I, Arnaud A, Racadot S & Guastalla JP. Cervix cancer and corpus cancer of the
uterus. Rev Prat, 2011, 61, (10): 1435-1442.
Tredan O, Ray-Coquard I, Chvetzoff G, Rebattu P, Bajard A, Chabaud S, Perol D, Saba C, Quiblier F,
Blay JY & Bachelot T. Validation of prognostic scores for survival in cancer patients beyond
first-line therapy. BMC Cancer, 2011, 11: 95.
Vallin M, Guillaud O, Morard I, Gagnieu MC, Mentha G, Adham M, Morelon E, Boillot O, Giostra E &
Dumortier J. Tolerability of everolimus-based immunosuppression in maintenance liver
transplant recipients. Clin Transplant, 2011, 25, (4): 660-669.
Varron L, Abad S, Kodjikian L & Seve P. Sarcoid uveitis: Diagnostic and therapeutic update. Rev Med
Interne, 2011, 32, (2): 86-92.
Varron L, Vignes S, Green L, Morelec I, Broussolle C & Seve P. Recurrent lymphangiectasia of the left
supraclavicular fossa: an unusual cause of paroxystic swelling. Arch Dermatol, 2011, 147,
(11): 1337-1338.